Focus: Allurion Technologies develops minimally invasive gastric balloon systems for obesity treatment, operating as a specialized medical device company in the metabolic diseases space. Founded in 2009 and headquartered in Natick, MA, the company focuses on endoscopic weight-loss solutions.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
A niche medical device play with validated technology but limited hiring activity and visibility; best for professionals seeking device commercialization experience in weight loss.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Allurion Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Allurion Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Endoscopically-placed gastric balloon offering supporting the company's diversified obesity intervention portfolio.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo